SanBio Company Limited (SNBIF OTCGREY) stock market data APIs
$16.4183
0(0%)
as of March 20, 2026
Try our APIs with
free plan!
SanBio Company Limited Financial Data Overview
Price chart is built with
Anychart
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company's research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction injury, chronic cerebral hemorrhage, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 for peripheral neuropathy; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Prev. Close
16.4183
Open
16.4183
High
16.4183
Low
16.4183
52 wk Range
3.85-16.45
Market Cap
1 284 M
Shares Outstanding
78 028 K
Beta
0.041
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SanBio Company Limited data using free add-ons & libraries
Get SanBio Company Limited Fundamental Data
SanBio Company Limited Fundamental data includes:
- Net Revenue:
- EBITDA: -3 785 999 872
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-17
- EPS/Forecast: -20.69
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SanBio Company Limited News
New
SB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks and Associated with Improvement in Function and Activities of Daily Living in Patients with Chronic Traumatic Brain Injury
Positive results from the one-year analysis of the Phase 2 STEMTRA trial will be presented for the first time at the 2022 American Academy of Neurology (AAN) Annual Meeting SB623 has the potential to...
SanBio: Notice Regarding Completion of Approval Filing for Japan SB623 Chronic TBI Program
TOKYO & MOUNTAIN VIEW, Calif., March 07, 2022--(BUSINESS WIRE)--The SanBio Group (SanBio Co., Ltd. of Tokyo, Japan, SanBio, Inc. of Mountain View, California, US, and SanBio Asia Pte. Ltd. of Singapor...
SanBio Joins the Newly Formed National TBI Registry Coalition (NTRC) as a Founding Member Organization
TOKYO & MOUNTAIN VIEW, Calif., December 15, 2021--(BUSINESS WIRE)--The SanBio Group (SanBio Co., Ltd. of Tokyo, Japan, SanBio, Inc. of Mountain View, California, US, and SanBio Asia Pte. Ltd. of Singa...
Business Partnership for Development and Commercialization of Medical Device Implant Utilizing MSC2 for the Regeneration of Esophageal Tissue in Humans
TOKYO & MOUNTAIN VIEW, Calif., November 16, 2021--(BUSINESS WIRE)--SanBio Company Limited (hereafter, "the Company") hereby announces that it entered into a business partnership agreement with D&P Bio...
Get SanBio Company Limited fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
